Source Bioscience Share Discussion Threads

[wilkie_hk] 11/6/2015 09:51

On the face of it a very encouraging trading statement this morning. However, as we have come to expect, it shies away from the numbers that we as investors hold these shares for. Let's hope there will be meat on the bones evident when the interims are released. There's enough in the statement to keep me invested here in the meantime.

[diamond1] 06/6/2015 10:36

Anything is better than TSTR at the moment, ha ha.

Although, at least we don't have Dr Rosso ramping it all the time now. He's to busy ramping SRSP. (Another from the Corvus stable.)

[peterz] 05/6/2015 22:34

Interesting - glad you got the point though.

Expecting good things. Better than TSTR!

[diamond1] 05/6/2015 00:28

A 'Shed load' has nothing to do with a shed of any description, although a lot of YOUNGER people think it does because they've never bothered to ask what it means, and have just made an assumption. It actually comes from a wagon losing it's load (Shedding it's load)and causing an obstruction and about twenty or thirty years ago, EVERYBODY knew the derivation.

Colloquially, it's come to mean 'a lot' but if it was a garden type shed, what size would it have to be, to be 'a lot'?

I get your point though. I've still got all mine as well.

Should have dumped them years ago. We never learn.

[peterz] 04/6/2015 23:53

I bought a shed load in medical solutions days. Still got them, no longer worth a shed, perhaps a fence panel....or ruler.

[diamond1] 04/6/2015 08:11

When you've held these as long as I have, (Medical Solution days.) HOPE is ALL you've got.

[yorkie123] 03/6/2015 12:30

Relax - up 1% this morning and hopefully good news at the AGM on 11th June.

[diamond1] 22/5/2015 09:59

SP unmoved for a month. That not the performance of a growing company, surely?

No posts only mine over the same period? Even 'Buywell' who usually has a constant stream of new info has disappeared.

It's the AGM on 11th June. Yet nobody has anything to say!

What's going on?

[diamond1] 19/5/2015 21:15

Is this suspended? It's behaving as if it is.

[peterz] 01/4/2015 13:54

They must be impressed. I guess they get to see more than us PI's!

[buywell2] 31/3/2015 16:51

Henderson Global go to 19.18%

[buywell2] 31/3/2015 07:28

thanks here is some more ...... the facility mentioned is in Boston



............ Cyprotex PLC Launch of new HTS laboratory in its US facility .........

31 March 2015

Cyprotex PLC

("Cyprotex" or "the Company")

Cyprotex launches new high throughput screening laboratory in its US facility

31st March, 2015; Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation (CRO), announced today the launch of a new high throughput screening laboratory at its US facility in Watertown near Boston. The laboratory replicates the highly successful ADME screening laboratory in Cyprotex's UK facility which has been developed in-house over the past 16 years using the combined expertise of our skilled software engineers and scientists. The unique platform allows Cyprotex to provide services which generate high quality consistent data in a rapid and cost-effective manner. All our customers, large and small, have access to and can benefit from the services available in North America.

The new facility houses state of the art automated liquid handling instruments and LC-MS/MS analytical instruments as well as a team of scientists and software engineers who are experienced in the field of high throughput screening. The integration has been led by our UK team who have been responsible for training staff and managing the smooth transfer of existing procedures and cross validation of the assays.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: "Expansion of our high throughput screening facility to the US has always been a much desired part of our growth strategy plans. Our unique software platform combined with state of the art automation and bioanalytical capabilities make us one of the only contract research facilities to be able to screen such large numbers of compounds in such a wide range of assays with relative ease. The medium and large Pharmaceutical companies who require high capacity and high quality screening with short turnaround times are realising the benefit of working with Cyprotex and as such the number of strategic deals are increasing and are a key factor in the growth of our business.






buywell2 says

Todays RNS is a great step forwards as HTS is a growth area.

Cyprotex now have the equipment, technology and trained staff to be able to tender for much larger volume contracts that require these three components in order to satisfy clients demands in terms of speed of delivery and quality of data provided and to satisfy existing USA contracts with the EPA (Environmental Protection Agency ) which could soon increase in size of chemical compounds tested ( contracts for the numbers have already been signed but the EPA has not yet fully pulled the trigger on the numbers tested as yet ) .

Things are now in place for larger contracts to be won.

2015 turnover looks set to improve as a result of this RNS





buywell2 31 Mar'15 - 07:17 - 2682 of 2682 0 0 edit

Re todays RNS ... a very timely development methinks


High Throughput Screening (HTS) Market worth $19,626.54 Million by 2018

According to the new market research report the “High Throughput Screening (HTS) Market by Technology (Cell Based, Ultra High Throughput Screening (UHTS), Label Free, Bioinformatics), by Applications (Target Identification, Primary Screening, Toxicology, Stem Cell) & by End Users (Pharmaceutical Industry, Biotechnology Industry, CRO) - Forecast to 2018” analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, and Rest of the World.



Browse 75 tables and 23 figures spread through 245 pages and in-depth TOC on "High Throughput Screening (HTS) Market by Technology (Cell Based, Ultra High Throughput Screening (UHTS), Label Free, Bioinformatics), by Applications (Target Identification, Primary Screening, Toxicology, Stem Cell) & by End Users (Pharmaceutical Industry, Biotechnology Industry, CRO) - Forecast to 2018"
hxxp://www.marketsandmarkets.com/Market-Reports/high-throughput-screening-market-134981950.html
Early buyers will receive 10% customization on reports.

This report studies the global high throughput screening (HTS) market over the forecast period of 2013 to 2018. The global HTS market was valued at an estimated $13,735.88 million in 2013 and is poised to grow at a CAGR of 7.4% from 2013 to 2018, to reach $19,626.54 million by 2018.

A number of factors such as technological innovations, open innovation models adopted by pharmaceutical companies, increasing drug discovery initiatives by academic institutions, and huge capital investments in the HTS technology by organizations are driving the growth of the HTS market. Moreover, the presence of a large untapped market in emerging countries and the incessant rise in outsourced drug discovery services especially in China and India are the various growth opportunities in this market. However, the capital intensive nature of HTS and difficulties in assay development for novel target classes are the factors that are curbing the growth of this market.

The HTS market is broadly classified into five segments, namely, technology, products, applications, end users, and geography. In the applications segment, the target identification market held the largest share of 45% in 2013. The availability of large compound libraries and well-equipped HTS laboratories, and technological advancements are the major factors driving the growth of this market. However, the primary screening market is poised to grow at the highest CAGR. The availability of a large number of potential lead compounds, emergence of several new detection technologies, and availability of novel primary and stem cell phenotypes are the factors that are responsible for the growth of this market segment. The growth in the outsourcing of drug services, especially in the Asian region, is a major reason for the high growth of the HTS market. In the end-users market, the pharmaceuticals segment dominated the market in 2013, with a market share of around 45%. In the technology market, the label-free technology segment is expected to register the highest growth in the forecast period. Label-free technology offers the direct detection ability, which was not possible with cell-based assays. Furthermore, it helps in reducing drug failure due to toxicity and can be applied to a majority of drug classes.

The global HTS market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). The large market share of the North American region is attributed to the increased investments by drug discovery firms for the promotion and advancement of technologies and increasing number of collaborations among companies and academia to develop and distribute innovative HTS products.

The major players in the HTS market include Agilent Technologies (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.), and Tecan group (Switzerland), among others.

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza,
17304,Preston Road,
Suite 800, Dallas, TX 75252
Tel: [phone]
Email: [e-mail]

[peterz] 30/3/2015 22:20

Honesty always appreciated, guv. Yeah right!

I have been a holder for years and hope to see a profit at some point, rather than a big loss.

Appreciate your stuff buy well.

[buywell2] 30/3/2015 21:01

If you look back over my posts I have been very critical of the BOD at times

My current stance is that they should provide additional Pharma Biotech pre clinical testing services to their TOP 50 in the world PHARMA clients in particular via the use of Cyprotex Labs in BOSTON in the USA , facilitated by

1. the installation of a VINDON cold storage facility at Cyprotex , so as to service the MASSIVE BOSTON Massachusetts Bio-Tech Life Sciences hub, together with

2. the installation of sequencing machines so as to provide the SBS overnight DNA sequencing service , thus maximising the SBS one stop shop theme.



Remember


Overnight DNA sequencing can only work to a radius of around 100 miles max due to transposrt time constraints.


At present Source Bioscience are missing out on the worlds BIGGEST area of drug discovery and development which occurs in Boston Massachusetts.












World's Largest Biotech Hubs: Boston and the San Francisco Bay








Boston vs. San Francisco Biotech.

Several trips to Boston this year to visit multiple companies piqued my interest about how the biotechnology industry in this area compared with the San Franciso Bay Area where I have worked for most of my career. Of course, I was aware the Boston region, especially Cambridge, hosts a large biotech community.

However, there are a number of biotech clusters in the US and my experience was that, while there is certainly a focus of biotech businesses in these areas, the breadth and depth of biotech in the San Francisco area functioned at a whole different level. However, recent trips to Boston made it clear that the number of, small start-ups, large established pharmaceuticals, incubators sites, large biotech-focused research institutions, really rivals the situation in the San Francisco area.

This prompted my curiosity as to how the details of the two regions compare.

How Big is Biotech in San Francisco and Boston?

The regions around the San Francisco Bay and Boston employ about 50,000 people in bioscience related jobs. However, most of the biotech jobs in Massachusetts appear to be more narrowly focused in pharmaceutical and biotech drug discovery. From the data at the Bureau of Labor and Statistics, in 2010 around 28,000 Massachusetts jobs—half the bioscience jobs—were focused on and biotech drug discovery.

However, only about a quarter (15,000) of the San Francisco Bay area jobs were in the category. It appears Massachusetts has almost twice as many people working in drug discovery and development. This disparity is also obvious when you look at the largest biotech companies in Massachusetts. Sanofi, Pfizer, Biogen-Idec, Novartis all major pharmaceutical companies with large research centers just outside Boston, employ over 10,000 people alone.

These four companies actually make up bulk of the difference in the employment numbers between Massachusetts and the San Francisco biotech clusters.


Boston Biotech Focuses on Drug Discovery and Development

This disparity between pharmaceutical-focused Massachusetts and the broader biotech segment in California is also reflected in the 897 new potential drugs in development or trials mentioned in the Massachusetts Biotechnology Council 2011 Industry snapshot versus the 699 touted in the California Biomedical Industry 2012 report for the entire state, not just the San Francisco Bay region.


San Francisco Biotech Has a Broad Base

However, the San Francisco Bay does appear to have a more diverse biotech community than Massachusetts with more companies overall. The exact number of companies is difficult to quantify as there are many small private enterprises. However, the Lab Rat website, which has a pretty comprehensive list of bioscience related companies, lists 195 biocompanies in Massachusetts and 240 around the San Francisco Bay.

Since the employment numbers are similar between Massachusetts and the San Francisco Bay Area, this means the there is has a much higher proportion of small biotech companies around the San Francisco Bay.


Venture Investment in San Francisco Biotech Larger than Massachusetts

The prevalence of small biotech in the San Francisco isn't surprising for anyone familiar with the quantity of venture investment in this area. Based on the PricewaterhouseCoopers MoneyTree Report approximately $2.3 billion was invested in San Francisco Bay area biotechnology and medical device companies in 2011, but only a little over half that, or $1.3 billion, was invested in the same sectors in Massachusetts. Actually, though, almost all the Massachusetts investments were in biotechnology, not medical diagnostic, companies.

Strictly in the biotech sector, San Francisco only has slightly more investment in this sector. It was the medical device sector where San Francisco companies drew over three times more capital than Massachusetts.

This difference likely explains much of the $20,000 disparity in average salary between Massachusetts biotech workers who average around $97,000 a year, and California biotech employees who make around $76,000 a year (although this number is for all of California so workers in the San Francisco area probably do a bit better).

Boston and San Francisco: The Principle Biotech Business Hubs

It is not clear which is the top biotech cluster but what is clear is that, combined, the Boston and San Francisco host the largest concentration of biotech activity in the world. Both areas have growing established broad-based biotech industry segments. Almost half of all US biotech investment is made in these areas, about 1/3 of the biotechnology employees work for companies in these areas, and about a quarter of US biotech companies are located in one of these clusters.

These two regions are the major drivers for global biotechnology innovation. With the economic climate of the last few years both regions have faced some challenges, but the unique mix of features that have enabled the biotech industry sector to thrive in these areas is not easily replicated and investment continues, so both regions appear positioned to retain their roles as biotechnology leaders. It seems that the global biotech industry will continue to revolve around these two hubs for some time.








Boston Biotech Cluster

The USA remains the global centre for the biotechnology and pharmaceutical industry. Currently the biotech industry is widely spread across North America, although San Francisco and Boston remain ahead the chasing pack. Boston is emerging incredibly rapidly to become the biggest, most connected, leading innovation biotech cluster in the world.

In the 2012, Ernst & Young Beyond Borders Biotechnology Report San Francisco ranked 1st in 6 of the 7 categories with Boston ranking 2nd in the same 6 categories, immediately showing the global presence and influence of both Boston and San Francisco. However, Boston has established itself as the current go-to biotech clusters and is likely to supersede San Francisco as the leading biotechnology cluster in the world. According to the 2012 Jones Lang Le Salle Global Cluster report Boston has already become the leading cluster in the world.

As the global biotechnology and pharmaceutical industry realigns itself, Boston continues to benefit and grow. Speak to any industry luminary and ask why they believe Boston is doing so well and the answer is consistent – CONNECTIVITY. Boston’s success is fuelled by world class universities and research establishments, innovation centres, research hospitals and world class service providers. Boston is home to some of the most famous research institutions in the world with Harvard, University of Massachusetts, Boston University and MIT all present in the region. Harvard and MIT are home to numerous Nobel laureates and world leading researchers. It is no coincidence therefore, that Boston is the leading recipient of National Institute of Health (NIH) funding in the US. In 2012 Boston accumulated over $2.2bn in NIH funding. The funding is shared between the research institutions at the universities and the research hospitals in the cluster. The cluster can boast 5 of the top 8 NIH funded hospitals in the USA. These hospitals are all global market leaders in biotechnology research.

According to estimates, Boston currently employs around 74,000 professionals within the pharmaceutical, medical device and biotechnology industries and 450,000 in the wider healthcare industry. These people are a mix of research professionals and people working in pharmaceutical companies. The list of companies within the cluster is truly astonishing with a mix of global pharma, emerging biopharmaceutical companies and innovative start-up or early-stage biotechs. Many of the global pharma are anticipating increasing head count in Boston. Pfizer, despite ongoing global restructuring, they are anticipating increasing hiring in the Boston area. Sanofi have committed to building their global oncology headquarters in the cluster, more than doubling its footprint in Boston. Sanofi also purchased Genzyme which accelerated their presence in the cluster. Novartis, despite huge layoffs in 2010 are anticipating increasing head count by 15%. Novartis are already the leading employer in Boston. Following Amgen’s acquisition of BioVex in 2011, they too have also signalled their intention to increase head count in the cluster despite their global headquarters being in California.

Alongside the globally recognised pharma companies, Boston has become home to many medium size companies who are currently showing considerable growth in an otherwise moderate growth industry. Shire, Alkermes, Vertex, Biogen IDEC, Alexion and Millennium (Takeda Oncology Company) are all present in Boston. The cluster has also given rise to some companies which are shaping the industry in multiple therapeutic areas. ARIAD Pharmaceuticals (oncology), Bluebird bio (gene therapy), Sarepta (rare diseases) BIND Bioscience, Cubist Pharmaceuticals, Forma Therapeutics and Mersana Therapeutics (antibody drug conjugates) being just some of the innovative companies with significant operations in the cluster.

Boston has also become a global hub for biotech investments. Within the biotechnology sector alone, Boston was second only to San Francisco in terms of Q4 2012 venture capital funding in the life science pulling in $278m. Over the course of the year in 2012, Boston accumulated a total of $1.32bn in venture capital funding for the life sciences. Although the pharmaceutical and biotechnology industry is global, clearly start-up companies thrive on the local ecosystem. It is no coincidence then that 80% of the total cluster lies within 300sq miles, pointing towards this hyper-connectivity which industry leaders talk of. The result is that Boston has on average three times as many biotech startups per sq mile than San Francisco.

With many venture capital companies like Atlas Ventures, Bain Capital Partners, Fidelity Biosciences, MVM Life Science Partners, PureTech Ventures and Third Rock Ventures, Boston is one of the leading centres for biotech investment.

With the desire of many biotechs to remain as trim as possible, the reliance on outsourcing and service provision is highly important. With service companies like Parexel, Charles River Laboratories, Covance and Perkin Elmer all present in the cluster, biotechs are not short of options to access the expertise they require in pre-clinical, clinical and manufacturing needed to develop their products.

The centre of biotechnology and pharmaceuticals in the cluster is Cambridge. Within Cambridge, start-up biotechs and global pharmaceutical companies have come together. Many companies start in Cambridge and then proceed to move to emerging suburbs within Boston such as the Seaport District, Longwood and the Academic Area. This is primarily due to cheaper rentals for laboratory space, however companies are still close enough to benefit from the considerable talent within the Boston cluster.

The proximity of companies has played a crucial role in the development of the cluster. Talent flows from company to company with many of the leading industry figures having worked their entire careers in the cluster. The proximity has helped to foster a collaborative approach in the cluster with people and companies sharing ideas and innovations, the very exemplar of how the future of this industry will succeed. Having such a close business community means that individuals are happy to put down roots in the area as they know they can always diversify their skills and are in demand.

With world leading academics, companies and world-class talent, it is little wonder that Boston is now being considered in some quarters as the leading Biotech cluster in the world. The Boston cluster has seen considerable growth in the past 5 years and that trend shows no sign of diminishing. Liftstream believes this cluster is an exceptional place to develop a career in the sector and with so many promising companies, it should be a hot-bed for future breakthrough research and innovation

[wilkie_hk] 30/3/2015 20:18

Buywell, you'd be advised not to deter investors/lurkers that wish to question the performance of the company. It would be fair say, whilst you postings are well researched and informed and appreciated, you do err, just a little on the optimistic side with this stock! I therefore welcome a balance from those that take the time to reason that everything in the garden is not quite so rosy. All responsble investors will want to make an informed decision over whether to buy, hold or sell and your unwelcoming attitude towards Norris is in danger of making this a this lesser board.

[norrishatter] 30/3/2015 17:28

Buywell

Hahaha. If I knew how to do smileys on here I'd put one on!

Honestly, I didn't mean to be negative; its just, well you know how it is - you put something on a forum and somebody replies and so you defend the position you took and somebody else comes back on that and so it goes on.

It looks like a company that could prove to be really interesting and I admire your passion (and amazing resourcefulness in all the stuff you dig out) in making a case for it. Passion deserves reward and I hope you get a great return on this investment.

I'm afraid once I get into an academic argument that I'm like a dog with a bone (and acquisitions and mergers is one of my bigger bones), so I hope you will forgive me for that.

All the very best (I'll sign off now I think and let actual investors use this board!)- given the previous success of the SBS management I suspect its more likely than not that they will produce a suitably large rabbit out of a hat for everyone (note clever Easter-tide reference(!)).

[buywell2] 30/3/2015 16:52

nice one norris


it's one less than a triplicate avatar

[norrishatter] 30/3/2015 13:00

Buywell,

Correct on all counts. Just spotted something that looked interesting and got involved in a discussion. My only interest is in how acquisitions turn out in practice. I am not an investor in SBS, have not been and as a result of the flak I'm now getting won't be in the future either.

Do you draw the same sort of conclusion about people who post consistently positive posts I wonder? That they have some sort of "agenda"? Trying to talk the share up because they want to make a gain and cash out?

I'm now bitterly regretting posting some analysis that I thought might be useful. I've never posted on one of these types of boards before and didn't realise that there would be the sort of aggression one finds on football fans websites when you dare to mention that the fan's favourite hasn't scored for 5 games.

PS: What's a "duplicate avatar"?

[buywell2] 30/3/2015 12:41

5 year SBS chart plotted V the FTSE 100....for those who think BIG stocks are better

'>

[buywell2] 30/3/2015 12:30

So just to get it right

Your 8 consecutive negative SBS posts are not because

1. You are an ex employee

2. You are not another duplicate avatar from another thread where I have correctly forecast a drop by say posting charts for example

and

3. You are not a former SBS investor that has sold out and is trying to talk the share price down to buy back in via a duplicate avatar name

[norrishatter] 30/3/2015 09:50

Buywell

In answer to your question - no I'm not a disgruntled former employee and I'm not sure that I appreciate this sort of comment. I'm a small scale private investor who happens to have an interest in this sector and have looked at other small caps in this area (e.g. Proteome, Oxford Pharmascience).

Source Bioscience is particularly interesting because of its recent acquisitions and if I have an "agenda" its that I have a bee in my bonnet about whether acquisitions really add value (you may like to Google "do mergers add value after all? CFO" to read some interesting stuff).

So that drew me to the message board and then you find someone with a lot to say (and I mean that in a friendly way) and then my weakness for internet message boards kicks in and one post leads to another and so on. My views are simply drawn from the numbers and for what its worth my opinion based on what I've looked at pre 2013 is that the management have done an excellent job in developing the company and the two acquisitions look to be very well chosen, particularly the way in which it gives the company exposure both east and west coast in the USA. So the issue is whether an excellent management team can beat the odds and produce value from acquisitions when the academic evidence is not generally in their favour.

Given that the posters on here seem like a genuinely good bunch I do really wish everyone well and hope the company does well for them. But it may be best if I gracefully withdraw at this point as I really don't want to upset anyone - with the caveat that I will undoubtedly have a look at the next interims to further my academic interest!

[buywell2] 30/3/2015 08:28

Re ADME Tox and specifically the Tox

elucidate yourselves mes amis agee



I am sure many here are over 57 .... A new assay called a Transporter Assay has NOT yet been made mandatory by the FDA , at present they are 'Guidance only'


Many elderly folks like you posters , take multiple medications as your posts demonstrate


That is to say you are putting multiple chemical compounds into your various organs via your blood and digestive routes that are mixing together to form NEW UNKNOWN chemical compounds which have NEVER been tested in pre clinical toxicology tests for adverse outcomes for phased clinical trials and hence approval



When such assays are made mandatory .... there will be many more failures and drug withdrawals and black box warnings issued.



From the USA ....


Drug Interactions data below is from 2008 .... so actual numbers of 1 in 25 over 57 year olds being ''at risk '' is now most likely worse and more likely to be around 5% of the USA over 57 year old population

50% of over 57 year olds take AT LEAST 5 medical products

medical product = A prescription drug from the doctor, or An 'over the counter' OTC purchase from local chemist , or a health supplement eg multi vitamin tablet





Drug Interactions
- One Survey
• National survey of 3005 community- residing older adults (>57 YO) in US
• 80% of individuals takes > 1 medical product (prescription, OTC, supplement)
• 50% takes at least 5 medical products
• 30% takes at least 5 prescription drugs

 1/25 at risk of major drug-drug interaction


March 7, 2015

click the 2 links




Drug Interaction Presentations

2015

•When should in vivo transporter-mediated drug-drug interaction studies be conducted? A scientific perspective. (PDF -1.4MB)
Lei Zhang, Ph.D., Office of Clinical Pharmacology, OTS, CDER, FDA
American Society for Clinical Pharmacology (ASCPT) Annual Meeting, New Orleans, LA ; March 7, 2015


•Drug Interactions - An Evolution in Drug Development (PDF - 3.15MB)
Shiew-Mei Huang, Ph.D.; Deputy Director, Office of Clinical Pharmacology, OTS, CDER, FDA
American Society for Clinical Pharmacology (ASCPT) Annual Meeting, New Orleans, LA; March 7, 2015

[buywell2] 30/3/2015 07:27

Norris has an agenda .... advfn Member since 06 Jan 2015 and 8 posts all on SBS


Are you a disgruntled ex employee ?

[bigman] 29/3/2015 19:25

Norris we are playing with numbers here, the company in 2012 had cash of 2.2m current borrowing of 750k and bank loan of 2.3m ( rump of buying the property) if they had not borrowed to buy the business there would be no loan and no finance costs as 2013 the loans would all have been paid.
So to use your numbers of adding all three together you HAVE to add the finance costs of this year to compare like with like, so 2+2 does equal 5.
Anyway I am going back to lurking, I have no concerns about the share price at this time, of course I would like to see it higher but hey I can wait.